0	12	Upregulation	upregulation	NN
13	15	of	of	IN
16	21	bcl-2	bcl-2	NN
22	24	by	by	IN
25	28	the	the	DT
29	41	Epstein-Barr	epstein-barr	JJ
42	47	virus	virus	NN
48	54	latent	latent	JJ
55	63	membrane	membrane	NN
64	71	protein	protein	NN
72	76	LMP1	lmp1	NN
76	77	:	:	:
78	79	a	a	DT
80	95	B-cell-specific	b-cell-specific	JJ
96	104	response	response	NN
105	109	that	that	WDT
110	112	is	be	VBZ
113	120	delayed	delay	VBN
121	129	relative	relative	JJ
130	132	to	to	TO
133	141	NF-kappa	NF-kappa	NNP
142	143	B	B	NNP
144	154	activation	activation	NN
155	158	and	and	CC
159	161	to	to	TO
162	171	induction	induction	NN
172	174	of	of	IN
175	179	cell	cell	NN
180	187	surface	surface	NN
188	195	markers	marker	NNS
195	196	.	.	.

198	200	An	an	DT
201	208	ability	ability	NN
209	211	of	of	IN
212	215	the	the	DT
216	228	Epstein-Barr	epstein-barr	JJ
229	234	virus	virus	NN
235	241	latent	latent	JJ
242	250	membrane	membrane	NN
251	258	protein	protein	NN
259	263	LMP1	lmp1	NN
264	266	to	to	TO
267	274	enhance	enhance	VB
275	278	the	the	DT
279	287	survival	survival	NN
288	290	of	of	IN
291	299	infected	infected	JJ
300	301	B	B	NNP
302	307	cells	cell	NNS
308	315	through	through	IN
316	328	upregulation	upregulation	NN
329	331	of	of	IN
332	335	the	the	DT
336	341	bcl-2	bcl-2	NN
342	350	oncogene	oncogene	NN
351	354	was	be	VBD
355	360	first	first	RB
361	370	suggested	suggest	VBN
371	373	by	by	IN
374	385	experiments	experiment	NNS
386	395	involving	involve	VBG
396	400	gene	gene	NN
401	413	transfection	transfection	NN
414	417	and	and	CC
418	421	the	the	DT
422	431	selection	selection	NN
432	434	of	of	IN
435	441	stable	stable	JJ
442	447	LMP1+	lmp1+	JJ
448	454	clones	clone	NNS
455	456	(	(	(
456	467	S.Henderson	S.Henderson	NNP
467	468	,	,	,
469	471	M.	M.	NNP
472	476	Rowe	Rowe	NNP
476	477	,	,	,
478	487	C.Gregory	C.Gregory	NNP
487	488	,	,	,
489	495	F.Wang	F.Wang	NNP
495	496	,	,	,
497	504	E.Kieff	E.Kieff	NNP
504	505	,	,	,
506	509	and	and	CC
510	521	A.Rickinson	A.Rickinson	NNP
521	522	,	,	,
523	527	Cell	Cell	NNP
528	540	65:1107-1115	65:1107-1115	CD
540	541	,	,	,
542	546	1991	1991	CD
546	547	)	)	)
547	548	.	.	.

549	556	However	however	RB
556	557	,	,	,
558	560	it	it	PRP
561	564	was	be	VBD
565	568	not	not	RB
569	577	possible	possible	JJ
578	580	to	to	TO
581	590	ascertain	ascertain	VB
591	598	whether	whether	IN
599	604	Bcl-2	bcl-2	NN
605	617	upregulation	upregulation	NN
618	621	was	be	VBD
622	623	a	a	DT
624	632	specific	specific	JJ
633	644	consequence	consequence	NN
645	647	of	of	IN
648	652	LMP1	lmp1	NN
653	663	expression	expression	NN
664	666	or	or	CC
667	669	an	an	DT
670	678	artifact	artifact	NN
679	681	of	of	IN
682	685	the	the	DT
686	695	selection	selection	NN
696	705	procedure	procedure	NN
706	713	whereby	whereby	WRB
714	718	rare	rare	JJ
719	725	Bcl-2+	bcl-2+	JJ
726	731	cells	cell	NNS
732	739	already	already	RB
740	747	present	present	JJ
748	750	in	in	IN
751	754	the	the	DT
755	763	starting	start	VBG
764	774	population	population	NN
775	780	might	might	MD
781	785	best	best	RB
786	788	be	be	VB
789	793	able	able	JJ
794	796	to	to	TO
797	805	tolerate	tolerate	VB
806	809	the	the	DT
810	821	potentially	potentially	RB
822	827	toxic	toxic	JJ
828	835	effects	effect	NNS
836	838	of	of	IN
839	843	LMP1	LMP1	NNP
843	844	.	.	.

845	847	We	we	PRP
848	857	therefore	therefore	RB
858	868	reexamined	reexamine	VBD
869	873	this	this	DT
874	879	issue	issue	NN
880	882	by	by	IN
883	888	using	use	VBG
889	892	two	two	CD
893	902	different	different	JJ
903	915	experimental	experimental	JJ
916	926	approaches	approach	NNS
927	931	that	that	WDT
932	939	allowed	allow	VBD
940	945	LMP1-	lmp1-	NN
946	953	induced	induced	JJ
954	961	effects	effect	NNS
962	964	to	to	TO
965	967	be	be	VB
968	977	monitored	monitor	VBN
978	989	immediately	immediately	RB
990	999	following	follow	VBG
1000	1010	expression	expression	NN
1011	1013	of	of	IN
1014	1017	the	the	DT
1018	1023	viral	viral	JJ
1024	1031	protein	protein	NN
1032	1035	and	and	CC
1036	1038	in	in	IN
1039	1042	the	the	DT
1043	1050	absence	absence	NN
1051	1053	of	of	IN
1054	1063	selective	selective	JJ
1064	1073	pressures	pressure	NNS
1073	1074	;	;	:
1075	1085	activation	activation	NN
1086	1088	of	of	IN
1089	1092	the	the	DT
1093	1101	NF-kappa	NF-kappa	NNP
1102	1103	B	B	NNP
1104	1117	transcription	transcription	NN
1118	1124	factor	factor	NN
1125	1128	and	and	CC
1129	1141	upregulation	upregulation	NN
1142	1144	of	of	IN
1145	1148	the	the	DT
1149	1153	cell	cell	NN
1154	1162	adhesion	adhesion	NN
1163	1171	molecule	molecule	NN
1172	1178	ICAM-1	icam-1	NN
1179	1183	were	be	VBD
1184	1188	used	use	VBN
1189	1191	as	as	IN
1192	1197	early	early	JJ
1198	1205	indices	index	NNS
1206	1208	of	of	IN
1209	1213	LMP1	lmp1	NN
1214	1222	function	function	NN
1222	1223	.	.	.

1224	1226	In	in	IN
1227	1230	the	the	DT
1231	1236	first	first	JJ
1237	1245	approach	approach	NN
1245	1246	,	,	,
1247	1253	stable	stable	JJ
1254	1260	clones	clone	NNS
1261	1263	of	of	IN
1264	1267	two	two	CD
1268	1274	B-cell	b-cell	NN
1275	1280	lines	line	NNS
1281	1289	carrying	carry	VBG
1290	1292	an	an	DT
1293	1297	LMP1	lmp1	NN
1298	1302	gene	gene	NN
1303	1308	under	under	IN
1309	1312	the	the	DT
1313	1320	control	control	NN
1321	1323	of	of	IN
1324	1326	an	an	DT
1327	1336	inducible	inducible	JJ
1337	1352	metallothionein	metallothionein	NN
1353	1361	promoter	promoter	NN
1362	1366	were	be	VBD
1367	1374	induced	induce	VBN
1375	1377	to	to	TO
1378	1385	express	express	VB
1386	1390	LMP1	lmp1	NN
1391	1393	in	in	IN
1394	1397	all	all	DT
1398	1403	cells	cell	NNS
1403	1404	.	.	.

1405	1415	Activation	Activation	NNP
1416	1418	of	of	IN
1419	1427	NK-kappa	NK-kappa	NNP
1428	1429	B	B	NNP
1430	1433	and	and	CC
1434	1446	upregulation	upregulation	NN
1447	1449	of	of	IN
1450	1456	ICAM-1	ICAM-1	NNP
1457	1465	occurred	occur	VBD
1466	1472	within	within	IN
1473	1475	24	24	CD
1476	1477	h	h	NN
1478	1481	and	and	CC
1482	1486	were	be	VBD
1487	1495	followed	follow	VBN
1496	1498	at	at	IN
1499	1501	48	48	CD
1502	1504	to	to	TO
1505	1507	72	72	CD
1508	1509	h	h	NN
1510	1512	by	by	IN
1513	1525	upregulation	upregulation	NN
1526	1528	of	of	IN
1529	1534	Bcl-2	bcl-2	NN
1534	1535	.	.	.

1536	1538	In	in	IN
1539	1542	the	the	DT
1543	1549	second	second	JJ
1550	1558	approach	approach	NN
1558	1559	,	,	,
1560	1562	we	we	PRP
1563	1569	tested	test	VBD
1570	1573	the	the	DT
1574	1584	generality	generality	NN
1585	1587	of	of	IN
1588	1592	this	this	DT
1593	1603	phenomenon	phenomenon	NN
1604	1606	by	by	IN
1607	1618	transiently	transiently	RB
1619	1629	expressing	express	VBG
1630	1634	LMP1	lmp1	NN
1635	1639	from	from	IN
1640	1641	a	a	DT
1642	1648	strong	strong	JJ
1649	1663	constitutively	constitutively	RB
1664	1670	active	active	JJ
1671	1679	promoter	promoter	NN
1680	1682	in	in	IN
1683	1684	a	a	DT
1685	1690	range	range	NN
1691	1693	of	of	IN
1694	1703	different	different	JJ
1704	1708	cell	cell	NN
1709	1714	types	type	NNS
1714	1715	.	.	.

1716	1719	All	all	DT
1720	1723	six	six	CD
1724	1730	B-cell	b-cell	NN
1731	1736	lines	line	NNS
1737	1743	tested	test	VBN
1744	1750	showed	show	VBD
1751	1759	NF-kappa	NF-kappa	NNP
1760	1761	B	B	NNP
1762	1772	activation	activation	NN
1773	1775	in	in	IN
1776	1784	response	response	NN
1785	1787	to	to	TO
1788	1792	LMP1	lmp1	NN
1793	1803	expression	expression	NN
1803	1804	,	,	,
1805	1808	and	and	CC
1809	1813	this	this	DT
1814	1817	was	be	VBD
1818	1826	followed	follow	VBN
1827	1829	in	in	IN
1830	1834	five	five	CD
1835	1837	of	of	IN
1838	1841	six	six	CD
1842	1847	lines	line	NNS
1848	1850	by	by	IN
1851	1861	expression	expression	NN
1862	1864	of	of	IN
1865	1871	ICAM-1	icam-1	NN
1872	1875	and	and	CC
1876	1881	Bcl-2	bcl-2	NN
1881	1882	.	.	.

1883	1885	In	in	IN
1886	1889	the	the	DT
1890	1894	same	same	JJ
1895	1906	experiments	experiment	NNS
1906	1907	,	,	,
1908	1911	all	all	DT
1912	1917	three	three	CD
1918	1928	non-B-cell	non-b-cell	JJ
1929	1934	lines	line	NNS
1935	1941	showed	show	VBD
1942	1950	NF-kappa	NF-kappa	NNP
1951	1952	B	B	NNP
1953	1963	activation	activation	NN
1964	1967	and	and	CC
1968	1974	ICAM-1	icam-1	NN
1975	1987	upregulation	upregulation	NN
1988	1991	but	but	CC
1992	1997	never	never	RB
1998	2001	any	any	DT
2002	2008	effect	effect	NN
2009	2013	upon	upon	IN
2014	2019	Bcl-2	bcl-2	NN
2019	2020	.	.	.

2021	2023	We	we	PRP
2024	2033	therefore	therefore	RB
2034	2042	conclude	conclude	VBP
2043	2047	that	that	IN
2048	2053	Bcl-2	bcl-2	NN
2054	2066	upregulation	upregulation	NN
2067	2069	is	be	VBZ
2070	2074	part	part	NN
2075	2077	of	of	IN
2078	2081	the	the	DT
2082	2089	panoply	panoply	NN
2090	2092	of	of	IN
2093	2101	cellular	cellular	JJ
2102	2109	changes	change	NNS
2110	2117	induced	induce	VBN
2118	2120	by	by	IN
2121	2125	LMP1	LMP1	NNP
2126	2129	but	but	CC
2130	2134	that	that	IN
2135	2138	the	the	DT
2139	2145	effect	effect	NN
2146	2148	is	be	VBZ
2149	2153	cell	cell	NN
2154	2158	type	type	NN
2159	2167	specific	specific	JJ
2167	2168	.	.	.

2169	2172	Our	our	PRP$
2173	2177	data	datum	NNS
2178	2182	also	also	RB
2183	2190	suggest	suggest	VBP
2191	2195	that	that	IN
2196	2202	whilst	whilst	IN
2203	2211	NF-kappa	NF-kappa	NNP
2212	2213	B	B	NNP
2214	2217	may	may	MD
2218	2220	be	be	VB
2221	2223	an	an	DT
2224	2233	essential	essential	JJ
2234	2243	component	component	NN
2244	2246	of	of	IN
2247	2251	LMP1	lmp1	NN
2252	2258	signal	signal	NN
2259	2271	transduction	transduction	NN
2271	2272	,	,	,
2273	2278	other	other	JJ
2279	2292	cell-specific	cell-specific	JJ
2293	2300	factors	factor	NNS
2301	2304	may	may	MD
2305	2307	be	be	VB
2308	2316	required	require	VBN
2317	2319	to	to	TO
2320	2326	effect	effect	VB
2327	2331	some	some	DT
2332	2341	functions	function	NNS
2342	2344	of	of	IN
2345	2348	the	the	DT
2349	2354	viral	viral	JJ
2355	2362	protein	protein	NN
2362	2363	.	.	.